These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 26381318)

  • 1. Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders.
    Di Minno G; Perno CF; Tiede A; Navarro D; Canaro M; Güertler L; Ironside JW
    Blood Rev; 2016 Jan; 30(1):35-48. PubMed ID: 26381318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?
    Di Minno G; Navarro D; Perno CF; Canaro M; Gürtler L; Ironside JW; Eichler H; Tiede A
    Ann Hematol; 2017 Aug; 96(8):1253-1270. PubMed ID: 28624906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current concepts on transmission of bacteria and parasites by blood components.
    Wendel S
    Vox Sang; 1994; 67 Suppl 3():161-74. PubMed ID: 7975485
    [No Abstract]   [Full Text] [Related]  

  • 4. Defining "adequate" pathogen reduction performance for transfused blood components.
    Goodrich RP; Custer B; Keil S; Busch M
    Transfusion; 2010 Aug; 50(8):1827-37. PubMed ID: 20374558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of the efficacy of medical screening of blood donors on preventing blood transfusion-transmitted infectious agents].
    Seck M; Dièye B; Guèye YB; Faye BF; Senghor AB; Toure SA; Dieng N; Sall A; Toure AO; Dièye TN; Diop S
    Transfus Clin Biol; 2016 May; 23(2):98-102. PubMed ID: 26681660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a national disaster on blood supply and safety: the September 11 experience.
    Glynn SA; Busch MP; Schreiber GB; Murphy EL; Wright DJ; Tu Y; Kleinman SH;
    JAMA; 2003 May; 289(17):2246-53. PubMed ID: 12734136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral safety of human plasma-derived medicinal products: impact of regulation requirements.
    Velthove KJ; Over J; Abbink K; Janssen MP
    Transfus Med Rev; 2013 Jul; 27(3):179-83. PubMed ID: 23886505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates.
    Klamroth R; Gröner A; Simon TL
    Transfusion; 2014 May; 54(5):1406-17. PubMed ID: 24117799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Orthopoxviruses: infections in humans. Position of the Blood Working Group of the Federal Ministry of Health].
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Sep; 53(9):957-72. PubMed ID: 20853093
    [No Abstract]   [Full Text] [Related]  

  • 10. Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands.
    Salunkhe V; van der Meer PF; de Korte D; Seghatchian J; Gutiérrez L
    Transfus Apher Sci; 2015 Feb; 52(1):19-34. PubMed ID: 25620756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of reasons for not implementing pathogen inactivation for platelet concentrates.
    Lozano M; Cid J
    Transfus Clin Biol; 2013 May; 20(2):158-64. PubMed ID: 23587612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 and HCV infections among antibody-negative blood donors.
    Prince AM
    N Engl J Med; 2004 Nov; 351(21):2232-5; author reply 2232-5. PubMed ID: 15559960
    [No Abstract]   [Full Text] [Related]  

  • 13. The risk of transmitting HCV, HBV or HIV by blood transfusion in Victoria.
    Whyte GS; Savoia HF
    Med J Aust; 1997 Jun; 166(11):584-6. PubMed ID: 9201178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Single-donor (apheresis) platelets and pooled whole-blood-derived platelets--significance and assessment of both blood products].
    Hitzler WE
    Clin Lab; 2014; 60(4):S1-39. PubMed ID: 24779310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Screening for viral genomes in blood transfusion].
    Coste J
    Transfus Clin Biol; 2000 Jun; 7 Suppl 1():11s-17s. PubMed ID: 10919218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation.
    Allain JP; Bianco C; Blajchman MA; Brecher ME; Busch M; Leiby D; Lin L; Stramer S
    Transfus Med Rev; 2005 Apr; 19(2):110-26. PubMed ID: 15852240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Status of NAT screening for HCV, HIV and HBV--experiences of the German Red Cross Blood Donation Services.
    Seifried E; Findhammer S; Roth WK
    Dev Biol (Basel); 2002; 108():23-7. PubMed ID: 12220139
    [No Abstract]   [Full Text] [Related]  

  • 18. Pathogen reduction combined with rapid diagnostic tests to reduce the risk of transfusion-transmitted infections in Uganda.
    Butler EK; McCullough J
    Transfusion; 2018 Apr; 58(4):854-861. PubMed ID: 29405306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond HIV, HBV and HCV--how to deal with other viruses?
    Minor PD
    Dev Biol (Basel); 2002; 108():15-9. PubMed ID: 12220138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood-Borne Pathogens: A Canadian Blood Services Centre for Innovation Symposium.
    Walsh GM; Shih AW; Solh Z; Golder M; Schubert P; Fearon M; Sheffield WP
    Transfus Med Rev; 2016 Apr; 30(2):53-68. PubMed ID: 26962008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.